Study Design. Longitudinal case-control animal model. Objective. To investigate effects of mesenchymal stem cell (MSC) treatment on multifidus muscle remodeling after intervertebral disc (IVD) lesion. Summary of Background Data. Lesion and degeneration of IVDs cause structural remodeling of the multifidus muscle. Proinflammatory cytokines are thought to contribute. MSC treatment restores IVD health after lesion but its effects on surrounding tissues remains unknown. Using an animal model of IVD degeneration, we assessed the effects of MSC treatment of IVDs on the structural remodeling and cytokine expression within the multifidus muscle.
L ow back pain (LBP) is the leading cause of disability internationally 1, 2 and is commonly associated with intervertebral disc (IVD) disease 3, 4 and structural [5] [6] [7] [8] [9] [10] and behavioral [11] [12] [13] [14] alterations to the multifidus muscle. Experimental IVD injury causes rapid atrophy 15 and inhibition 16 of multifidus within days, then later structural remodeling (e.g., fatty infiltration, fibrosis). 17 Such changes have relevance for spine control and pain. 18, 19 Stem cell therapies for IVD injury/degeneration have promising results for prevention/restoration of IVD properties. 20 Whether these treatments also influence the health of surrounding tissues, including back muscles, remains unknown.
In acute LBP, reduced spinal excitability 16 mediates reduced cross-sectional area (CSA) of multifidus. 5 Magnetic resonance imaging analysis in chronic LBP reveals multifidus fatty infiltration [7] [8] [9] and atrophy, 21 potentially related to disuse. Animal studies reveal a temporal pattern of multifidus remodeling following induction of IVD disease characterized by increased adipose 22 and connective tissue, 22, 23 slow-to-fast muscle fiber type transformation, 17, 22 but no changes in whole muscle/muscle fiber CSA. 22 Muscle remodeling in the intermediate period appear mediated by an inflammatory response involving upregulated proinflammatory cytokines gene expression (e.g., tumor necrosis factor [TNF] , interleukin 1beta ). 22 This suggests LBP-induced muscle changes are mediated by different mechanisms and time courses; each with relevance for spinal health.
Mesenchymal stem cell (MSC) treatment is a promising IVD therapy 20, 24 ; it both prevents and repairs IVD degeneration, depending on the time of treatment. 24 Whether MSC IVD treatment also affects health of surrounding tissues, including multifidus, and if this differs with time of application but has not been determined.
The present study aimed to investigate the effect of MSC application into an injured IVD on structural and inflammatory changes within multifidus. We studied whether MSC treatment prevents (early MSC application) or restores (late MSC application) multifidus remodeling after experimental IVD lesion. Furthermore, we investigated whether early/late MSC treatment modified proinflammatory cytokine gene expression within the muscle.
MATERIALS AND METHODS

Animals
Forty-five merino wethers (aged 3-4 yr) as part of a study investigating MSC treatment on IVD lesions were used. 24 All procedures were carried out with the approval of the institutional animal care and ethics committee.
Surgical Procedure, Intervertebral Disc Lesion, Mesenchymal Stem Cell Injection, Postoperative Care, and Tissue Harvesting
Ten age-and weight-matched sheep, which did not undergo a surgical procedure, receive an IVD lesion, or an MSC injection, were assigned to the control group (histological analysis of the multifidus muscle of these animals has been reported previously). 22 Thirty-five animals underwent surgery as previously described. 17 Briefly, an extraperitoneal surgical approach was used to induce a 20 mm wide Â 6 mm deep annulus fibrosis lesion (without penetrating the nucleus pulposus) on the left anterolateral region of IVDs at L1-2, L3-4, and L5-6 ( Figure 1A ). This lesion induces progressive disc degeneration mimicking many of the pathological and molecular changes in patients. 25 For 10 days after surgery, animals were closely monitored in pens to ensure wound healing, absence of gait abnormalities, or surgical complications. At 4 (early treatment group; n ¼ 24) or 12 (late treatment group; n ¼ 12) weeks after the initial surgery, half of each group of animals received MSC (10 7 culture-expanded heterologous bone marrow-derived ovine cells/0.2 mL phosphate-buffered saline, 24 which were selected as a clinically relevant cell source that has been evaluated for a variety of therapeutic applications particularly for applications related to stimulation of chondrogenesis 26 ) or Phosphate-buffered saline carrier (untreated injured group-histological analysis of the multifidus muscle of these animals has been reported previously 22 ) injected into the nucleus pulposus of the operated IVD via the right side under direct surgical visualization ( Figure 1B) . All animals were cohoused in an open paddock with unrestricted exercise. Multifidus muscle ( Figure 1C, D) was harvested at 3 (n ¼ 6: early treatment/untreated; n ¼ 4 control) or 6 (n ¼ 6: early or late treated/untreated; n ¼ 6 control) months after the IVD lesion and processed as previously described 17 ( Figure 1G ).
Analysis of Muscle, Connective, and Adipose Tissues
Paraffin-embedded multifidus muscles from L4 (lesion, contralateral) were sectioned (8 mm), their muscle, connective, and adipose tissue composition analyzed using Masson trichrome and Van Gieson stains ( Figure 1E ). Entire multifidus sections were imaged (Scanscope AT Turbo, Aperio, Vista, CA). Each tissue type (adipose, muscle, connective tissue) was identified based on color 22 ( Figure 1F ) and CSAs were quantified using ImageJ (NIH, Bethesda, MD).
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Muscle Fiber-Type Analysis
The immunohistochemistry assay was performed as previously described 17 using reagents mentioned in Table 1 . Whole sections of multifidus were imaged (ScanScope AT Turbo, Aperio) and muscle fiber type proportion and CSA were quantified. Multifidus was divided into 36 regions, 17 with two images taken within each region. From each image, the proportions of slow (stained black/brown), fast (stained red/pink), and intermediate fibers (combination of slow and fast) were determined based on staining color and intensity ( Figure 1F ). 17 CSA of five to six randomly chosen fibers of each type was quantified using ImageJ (NIH). 22 
Cytokine Gene Expression
Total RNA was extracted from the deepest fascicle of multifidus at L2 using an RNeasy Mini Kit (Qiagen, Hilden, Germany). RNA was reverse transcribed with the Super Script III first-strand synthesis kit (Invitrogen, Carlsbad, CA) and real-time polymerase chain reaction preformed using the IQ SYBR Green Mastermix (Bio-Rad Laboratories, Hercules, CA). Gene expressions were first converted to a percentage of the housekeeping gene GAPDH then to fold difference to the mean of the control values. Primer pairs used in this experiment are listed in Table 2 .
Statistical Analysis
All measures were compared between sides (injured/left vs. uninjured/right; within subject factor) and groups at 3 (control vs. untreated injured vs. early treatment) and 6 (control vs. untreated injured vs. early and late treatment groups; between subject factor) months after injury with separate repeated measures analysis of variance. Post-hoc analysis involved Duncan multiple range test. Comparison of control to untreated injured animals has been reported earlier. 22 Data are expressed as mean AE SD. Significance was set at P < 0.05.
RESULTS Whole Muscle, Connective, and Adipose Tissue Analysis
Early Treatment Group-3 Months Table 3 presents statistical analysis of early MSC treatment at 3 months. In contrast to the previously reported 22 lack of difference between control and untreated injured for any measure, connective tissue CSA was less after early MSC treatment than control and had a nonsignificant tendency to be less than untreated injury ( post hoc P ¼ 0.058) on both sides ( Figure 2A ). Muscle and adipose tissue CSA did not differ between MSC treated and control/untreated injured ( Figure 2A ). Table 4 presents statistical analysis of 6-month data for early and late MSC treatment. MSC treatment during the acute phase of IVD degeneration prevented the increased in Figure 3A ). Connective tissue CSA was less for the MSC treatment than untreated injury group. MSC treatment induced multifidus hypertrophy on both sides relative to control/untreated injury ( Figure 3A) .
Early Treatment Group-6 Months
Late Treatment Group-6 Months MSC-treated sheep at 12 weeks would already have established IVD degeneration. 24 Yet, muscle, adipose, or connective tissue CSA of muscle harvested at 6 months was not different between late MSC treated and control ( Figure 3A ). This contrasts with increased adipose and connective tissue CSA in untreated animals 22 ( Figure 3A ). Late connective tissue CSA was less than untreated injured. Muscle CSA was smaller for the late than for the early treated group at 6 months ( Figure 2B and Figure 4 ) and ( Figure 3B and Figure 4 ).
Muscle Fiber Analysis
Early Treatment Group-3 Months As for untreated injured 22 early MSC treatment did not change the proportion of slow, fast, and intermediate muscle fibers relative to control and untreated injured ( Figure 2B ). CSA of slow or fast muscle fibers did not differ between groups, but intermediate muscle fiber CSA was less for early treatment ( Figure 2D ).
Early Treatment Group-6 Months At 6 months early MSC treatment did not prevent muscle fiber changes induced by IVD lesion. 22 The proportion of slow fibers was reduced on both sides at 6 months relative to control ( Figure 3B ), and not different to untreated injured. Intermediate fibers increased after early MSC treatment relative to control and untreated injured. The proportion of fast fibers was unchanged by early MSC treatment, although this had been reported in untreated injury. 22 There was no difference in CSA of slow or intermediate muscle fibers (Figure 3D ), but fast fibers were smaller on the injured side for all groups.
Late Treatment Group-6 Months Late MSC treatment had a lower proportion of slow fibers than control and no difference to untreated injured on both sides ( Figure 3B ). The proportion of intermediate fibers was greater for the late treatment group than control and 
IL-1b indicates interleukin 1beta; TGF-b1, transforming growth factor-beta 1; TNF, tumor necrosis factor. 
C indicates control animals; Conn., connective tissue; CSA, cross-sectional area; E3, early MSC treatment 3-month muscle analysis; fast, fast muscle fiber; I, untreated injured animals; IL-1b, interleukin-1beta; intermed., intermediate muscle fiber; slow, slow muscle fiber; TGF-b1, transforming growth factor-beta1; TNF, tumor necrosis factor.
untreated injured for the injured side, but only the control animals on the noninjured (right) side. Proportion of fast fibers was not different between late MSC-treated and other groups. CSA of muscle fibers was unchanged for slow and intermediate muscle fibers, but smaller for the fast fibers on the injured side for all groups ( Figure 3D ).
Proinflammatory Cytokine Gene Expression
Early Treatment Group-3 Months Early MSC treatment did not alter the expression of TNF or transforming growth factor-beta 1 (TGF-b1) at 3 months relative to control/untreated injured. IL-1b expression was less on both sides of the MSC-treated animals than control/ untreated injured ( Figure 2C ).
Early Treatment Group-6 Months At 6 months, the early MSC-treatment group had greater TNF expression than control animals on the injured but not noninjured side ( Figure 3C ), and was greater than the increased previously observed for untreated injured.
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TGF-b1 expression was greater on the injured side of the early MSC-treated than untreated injured animals. IL-1b expression in the early MSC-treated group was similar to control/untreated injured ( Figure 3C ). Increased TNF and IL-1b expression in untreated inured relative to controls 22 narrowly missed significance unlike the previous study that retained higher power due to fewer analyses.
Late Treatment Group-6 Months
Late MSC treatment increased TNF expression on both sides relative to controls and on the injured side relative to untreated injured ( Figure 3C ). Late MSC treatment had a tendency (P ¼ 0.059) for greater TGF-b1 expression than control on the injured side only. Expression of IL-1b was not different between groups.
DISCUSSION
Treatment of injured IVD (early or late) has positive potential to prevent or restore structural remodeling of adipose and connective tissue of adjacent muscles, but the timing of treatment is important. MSC treatment modified the muscle's inflammatory response but did not prevent, and in the late treatment group actually increased TNF expression or the transformation of muscle fibers induced by IVD injury. This will affect the muscle's functional capacity and suggests MSC treatment alone cannot prevent/reverse all effects of IVD lesion.
Mechanisms for Mesenchymal Stem Cell Treatment of Intervertebral Disc to Affect Muscle Changes
MSC treatment of IVD lesion not only affects the injured IVD, 24 but also surrounding muscles. Although MSC differentiation into various cell types has been considered the primary role in treatment of musculoskeletal disorders, recent research suggests a role of paracrine effects. 27 Paracrine signaling factors secreted from MSCs have antifibrotic, immunomodulatory, and anti-inflammatory effects in surrounding tissues. 28, 29 MSCs interact with immune cells such as polarizing macrophages from a pro-(M1) to anti-inflammatory (M2) state. 30, 31 M1 macrophages express high levels of proinflammatory cytokines (TNF/IL-1b). M2 macrophages express TGF-b1 in an anti-inflammatory role, 32 but undetectable IL-1b. 33, 34 MSC-induced polarization toward anti-inflammatory M2 macrophages in multifidus observed here could explain reduced IL-1b expression in early treated animals and increased TGF-b1 at 6 months. Upregulated TNF expression indicates MSC treatment did not dampen the proinflammatory response of TNF after IVD lesion. Alternatively, positive effects of MSC treatment of IVD on muscle physiology might be an indirect 
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Mesenchymal Stem Cell Treatment Prevents Increased Adipose Tissue
Fatty infiltration is common in back muscles, particularly multifidus, in LBP, 7, 9 and develops by 6, but not 3, months, on the injured side after IVD injury in sheep. 22 Although mechanisms are poorly understood, data from humans and animals imply rapidly developing adipogenesis 15, 23 recovers, 38, 8 with subsequent gradual development of sustained fatty infiltration during 3 to 6 months. 22 Our data indicate MSC treatment of an injured IVD either early (preventing IVD degeneration) or late (restoring IVD degeneration) prevents fatty infiltration, suggesting ongoing IVD health is more important than initial injury for driving fatty infiltration.
TNF 39 and TGF-b1 40 regulate adipocyte development from either progenitor MSC 41 or transdifferentiation from myoblasts. 42 TGF-b1 antagonizes adipogenesis, 40 whereas TNF has both adipogenic and antiadipogenic effects depending on concentration, time point, and receptor expression. 43 Although upregulated TNF expression paralleled increased adipose CSA in untreated animals, 22 the present study showed upregulation of both TNF and TGFb1 following MSC treatment. Thus, either proadipogenic effects of TNF were antagonized by increased TGF-b1 expression or MSC treatment changed TNF to an antiadipogenic function. Muscle unloading reduces expression of factors that inhibit myoblast transdifferentiation to adipocytes, 35 thus maintained muscle activation by improved IVD health might explain maintained adipose CSA.
Mesenchymal Stem Cell Treatment Prevents Increased Connective Tissue
MSC treatment of the IVD prevented the accumulation of connective tissue in multifidus after untreated IVD injury. 22 Muscle fibrosis accompanies muscle injury for muscle repair 44 and increases with aging. 45 Profibrotic cells transdifferentiate from myogenic cells 46 when TGFb1 increases. 44 This appears inconsistent with our data of unchanged connective tissue despite increased TGF-b1, but could be explained by complex interplay between multiple cytokines and differing temporal expression (e.g., connective tissue reduced at 3, but not 6, months after early treatment). Antifibrotic effects of MSC treatment of IVD were accompanied by an acute short-term downregulation of IL-1b (suggesting its anti-inflammatory effect). The subsequent loss of IL-1b -mediated inhibition of TGF-b1 47 between 3 and 6 months may explain upregulation of TGF-b1 by 6 months, and the recovery of connective tissue. Restoration of connective tissue CSA to control levels at 6 months may represent accelerated fibrosis in response to increased TGF-b1 expression, but from a reduced baseline at 3 months. Improved muscle activation could also explain the absence of fibrosis potentially through muscle unloading. 36 
Mesenchymal Stem Cell Treatment Does not Prevent Muscle Fiber Transformation, but Causes Early Hypertrophy
Despite promising effects on muscle fat and fibrosis, MSC treatment of injured IVD did not prevent muscle fiber type transformation; however, early treatment augmented multifidus. Contrary to clinical predictions, 5, 6, 10 earlier data of untreated IVD lesions 22 show no loss of muscle CSA (whole muscle or muscle fiber) by 6 months. This concurs with human imaging within 3 months 8 and muscle fiber histology in rabbits 23 after IVD injury. This does not preclude very early (within days 5, 15 ) and late (>6 mo 6, 10 ) muscle atrophy. 22 Multifidus hypertrophy after early, but not late treatment has several explanations. First, MSCs regulate muscle atrophy/hypertrophy. 48 MSC-treated culture media prevent muscle atrophy through growth factor secretion, 48 which could promote hypertrophy. Second, IL-1b inhibits the growth factor pathways. 49 Downregulated IL-1b expression at 3 months after early treatment would reduced IL-1b-mediated inhibition of the growth factor pathway leading to its overactivation and hypertrophy. Untreated IVD injury upregulates genes in the growth factor pathway 22 but did not induce hypertrophy possibly via antagonist effects of TNF on signaling molecules (e.g., protein kinase B [Akt1]; phosphoinositide 3-kinase 50 ). TNF effects may be modified after MSC treatment by interaction with other cytokines.
Because individual muscle fiber CSA did not increase, hypertrophy must involve increased fiber number potentially mediated by differentiation of multipotent stem cells into muscle fibers. Improved IVD function mediated by MSC treatment is unlikely to explain hypertrophy as this would be expected to maintain, but not hypertrophy the muscle.
Mechanisms including proinflammatory cytokine expression 22 and muscle loading 51 regulate transformation, which are implied by increased intermediate fiber proportion. Slow fiber proportion potentially reduces by transformation 52 or selective slow fiber loss 53 and fast fiber proliferation. 54 MSC treatment neither prevents/reverses muscle fiber transformation following IVD nor prevents upregulated TNF expression at 6 months, which coincided with fiber type transformation. This remodeling persisted despite restored IVD health at 6 months. 24 Muscle-synthesized TNF promotes preferential fast fiber differentiation 55 and TGF-b1 causes myotubules to preferentially develop into fast fibers. 54 Parallel time courses suggest such a cytokine-driven process. Data of untreated animals also imply independence of IVD pathology and muscle changes, because IVD pathology (disc height, biomechanics, histopathology, and biochemistry) is maximal at 3 months 24 yet muscle changes are not apparent until 6 months 17 in sheep 22 and rabbits. 23 Failure of MSC treatment to prevent this inflammatory process, despite IVD healing, could explain our data. Fast heavy chain myosin genes undergo increased transcription in absence of muscle stretch/force. 37, 56 Although MSC treatment may restore IVD biomechanics, 24 the pattern of multifidus stretch/load may be modified (as in persistent LBP 11 ), causing muscle fiber transformation. Reduced slow muscle fiber proportion has functional consequences for spine health. Loss of fatigue-resistant fibers could limit the capacity to sustain activity required for ongoing spine control. 57 
Implications
These data highlight the potential of MSC treatment of IVD lesion; however, not all structural remodeling was overcome by restored IVD health. Prevention of fatty infiltration and fibrosis during the subacute/early chronic phase implies widespread effects of MSC treatment to surrounding tissues. Persistent upregulation of proinflammatory cytokine expression in multifidus and changes in muscle fiber transformation imply other interventions such as exercise or antiinflammatory treatments may complement MSC treatment for more complete recovery after IVD injury.
Key Points
IVD injury induces structural remodeling of the multifidus muscle, including slow-to-fast muscle fiber transformation, and increased adipose/ connective tissue. MSC treatment of the IVD prevents fibrosis and fatty infiltration of the adjacent multifidus muscles. MSC treatment of the IVD cannot prevent an upregulation of proinflammatory cytokines within the multifidus muscle, or the slow-to-fast transformation of muscle fibers. Muscle fiber changes are likely to affect multifidus muscle function for spine health and the effects of MSC treatment on injured IVDs may require combination with other interventions.
